Transgene SA
11 rue de MOLSHEIM, 67082
Strasbourg
Cedex
France
Tel: 011-33-3-88-27-91-21
Fax: 011-33-3-88-27-91-11
Website: http://www.transgene.fr/
302 articles with Transgene SA
-
Transgene: 2022 Full-year Results and Business Update
3/16/2023
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2022 and provides an update on its product pipeline.
-
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
3/9/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.
-
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
1/6/2023
Regulatory News: Transgene announces it has received clinical trial application approval from the French National Agency for the Safety of Medicines and Health Products to proceed with a Phase I clinical trial of TG6050, a novel oncolytic virus that will be administered intravenously in patients with advanced non-small cell lung cancer.
-
Transgene Announces Financial Calendar for 2023
1/4/2023
TRANSGENE announced its financial reporting dates for 2023.
-
Transgene Announces Upcoming Investor Meetings - December 15, 2022
12/15/2022
Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in January and February 2023, as set out below.
-
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
11/14/2022
Transgene and BioInvent International AB announced that a paper co-authored by researchers from Transgene and BioInvent is the recipient of this year’s Journal for ImmunoTherapy of Cancer “Best Oncolytic and Local Immunotherapy Paper” Award.
-
Transgene Reports Business Update And Q3 2022 Financial Position
11/7/2022
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its business update and its financial position for the quarter ending September 30, 2022.
-
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
11/2/2022
Transgene (Euronext Paris: TNG) today announces that following an interim analysis of its randomized controlled Phase II clinical study comparing TG4001 in combination with avelumab to avelumab alone in patients with HPV16-positive anogenital tumors (NCT: 03260023), the Independent Data Monitoring Committee (IDMC) has recommended the study continue.
-
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
9/27/2022
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, will host an R&D event for investors and research analysts in Paris.
-
During an R&D presentation Tuesday, Transgene executives and oncology experts highlighted promising therapeutic progress in its programs - focusing on its developmental cancer vaccines.
-
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
9/12/2022
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces positive confirmatory data from the Phase I trial evaluating TG6002 administered intravenously in combination with oral 5-FC in patients with advanced gastrointestinal carcinomas.
-
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
9/7/2022
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for the six-month period ended June 30, 2022 and provides an update on the progress of its portfolio of clinical-stage drug candidates.
-
Transgene Announces Upcoming Investor Meetings - Aug 31, 2022
8/31/2022
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that Management will participate in the upcoming investor events.
-
Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.
-
BioInvent and Transgene Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA(R)
6/28/2022
BioInvent International AB and Transgene announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD's anti-PD-1 therapy KEYTRUDA® in a Phase 1/2a clinical trial for the treatment of patients with solid tumors.
-
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®
6/28/2022
Transgene and BioInvent International AB announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.
-
Transgene and BioInvent Announce Positive Progress for BT-001
6/27/2022
Transgene and BioInvent International AB jointly announced positive progress and safety data of the ongoing Phase I/IIa trial evaluating BT-001 in patients with solid tumors, including melanoma.
-
At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.
-
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
6/6/2022
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it presented updated preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, in a poster session at the American Society of Clinical Oncology annual meeting.
-
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
5/27/2022
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology annual meeting.